Pharmacological Treatment of Obesity: Current Standards and Future Perspectives

Romijn, J. A.; Smit, J. W. A.; Pereira, A. M.; Corssmit, E. P. M.; Pijl, H.
February 2006
Immunology, Endocrine & Metabolic Agents - Medicinal Chemistry;Feb2006, Vol. 6 Issue 1, p119
Academic Journal
The long-term effects on weight have only been studied for orlistat and sibutramine. The net effects of these drugs vary between 2-5% loss of weight after 1-2 years of treatment. However, the effects of orlistat and sibutramine on morbidity and mortality have not been studied extensively. In the past decade a huge amount of new knowledge has been gathered on the physiology of energy metabolism, satiety, gut-brain interactions, adipokines, adipogenesis, hypothalamic regulation etc. These studies have provided a multitude of new pharmacological targets for the treatment of obesity. Preclinical and clinical studies will have to prove the efficacy and safety of new drugs aimed at these new targets. The ultimate goal will be to reduce the increased morbidity and mortality, associated with obesity.


Related Articles

  • Weight-Loss Pharmacotherapy: A Brief Review. Huizinga, Mary Margaret // Clinical Diabetes;Fall2007, Vol. 25 Issue 4, p135 

    The article reviews current pharmacological options for weight loss and provides a brief synopsis of potential future options. It says that the medical treatment of obesity is aimed at decreasing appetite, alterating absorption of calories and increasing thermogenesis. It states that the two...

  • New Trends in Medicinal Chemistry Approaches to Antiobesity Therapy. Jinhwa Lee; Kwang-Seop Song; Jahyo Kang; Suk Ho Lee; Junwon Lee // Current Topics in Medicinal Chemistry;Apr2009, Vol. 9 Issue 6, p564 

    The prevalences of overweightedness and obesity are increasing globally at frightening rates, driven by social and economic changes. Furthermore, obesity is associated with the pathogeneses of major diseases, particularly diabetes and cardiovascular diseases. However, no satisfactorily safe,...

  • Diet drugs require low-calorie diet.  // Healthy Weight Journal;Nov/Dec2000, Vol. 14 Issue 6, p82 

    Reports on the influence of reduced-calorie diet on the effectiveness of orlistat and sibutramine in treating obesity. Mechanism of action of orlistat; Adverse effects of sibutramine.

  • Drug Treatment of Obesity: Established and Emerging Therapies. Isidro, M. Luisa; Cordido, Fernando // Mini Reviews in Medicinal Chemistry;Jun2009, Vol. 9 Issue 6, p664 

    Available anti-obesity pharmacotherapy options remain very limited. The development of more effective drugs has become a priority. The potential strategies to achieve weight loss are to reduce energy intake, by stimulating anorexigenic signals or by blocking orexigenic signals, and to increase...

  • Anti-obesity Agents: A Focused Review on the Structural Classification of Therapeutic Entities. Sangmi Oh; Koon Soon Kim; Young Sun Chung; Minho Shong; Seung Bum Park // Current Topics in Medicinal Chemistry;Apr2009, Vol. 9 Issue 6, p466 

    In addition to its enormous impacts on an individual's quality of life, obesity is a daunting health problem in the world today and the increasing rate of obesity is now causing a severe burden on health care systems. Fortunately, the normalization or reduction of increased body fat reverses the...

  • Pharmacotherapy of Obesity: An Update. Schurgin, Sunita; Siegel, Richard D. // Nutrition in Clinical Care;Jan-Apr2003, Vol. 6 Issue 1, p27 

    There has been an epidemic of obesity in the last decade, In spite of the rising numbers of people who are overweight and obese, medical treatment of obesity is currently where medical treatment of hypertension was in the 1950s with only two Food and Drug Administration-approved medications for...

  • Safety of drug therapies used for weight loss and treatment of obesity. Ioannides-Demos, Lisa L.; Proietto, Joseph; Tonkin, Andrew M.; McNeil, John J. // Drug Safety;2006, Vol. 29 Issue 4, p277 

    Some of the medications used for weight loss in the management of obesity have been associated with unacceptable morbidity and mortality. Safety concerns have led to the withdrawal of aminorex, followed by the fenfluramines in 1997, and phenylpropanolamine (norephedrine) in 2000. Aminorex was...

  • Currently Available Drugs for the Treatment of Obesity: Sibutramine and Orlistat. Chaput, J.-P.; St-Pierre, S.; Tremblay, A. // Mini Reviews in Medicinal Chemistry;Jan2007, Vol. 7 Issue 1, p3 

    The currently available drugs for long-term treatment of obesity are sibutramine and orlistat. They have been shown to be able to induce significant weight loss, with important co-morbidity reduction, allowing the maintenance of reduced body weight for at least 1-2 years. Cardiostimulating and...

  • DRUGS FOR OBESITY. Mead, Mike // Practice Nurse;9/10/2004, Vol. 28 Issue 4, p64 

    Focuses on prescription drugs available to help obese patients to lose weight. Clinical indications of Sibutramine and Orlistat; Contraindications and side effects of the drugs; Importance of monitoring patients who are taking drug therapy.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics